ALSMA Fundamental Analysis - SMAIO SA

Name: SMAIO SA (ALSMA) Stock
Brand: SMAIO SA
Rating: 5.5 (3 reviews)

Fundamental Rating

Taking everything into account, ALSMA scores 3 out of 10 in our fundamental rating. ALSMA was compared to 60 industry peers in the Health Care Equipment & Supplies industry. While ALSMA seems to be doing ok healthwise, there are quite some concerns on its profitability. ALSMA is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALSMA had negative earnings in the past year.

ALSMA had a negative operating cash flow in the past year.

ALSMA had negative earnings in 4 of the past 5 years.

In multiple years ALSMA reported negative operating cash flow during the last 5 years.

1.2 Ratios

With a Return On Assets value of -19.91%, ALSMA is not doing good in the industry: 73.33% of the companies in the same industry are doing better.

With a Return On Equity value of -34.30%, ALSMA is not doing good in the industry: 71.67% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-19.91%
ROE	-34.3%
ROIC	N/A

ROA(3y)0.22%

ROA(5y)-14.26%

ROE(3y)-3.31%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALSMA's Gross Margin of 76.70% is amongst the best of the industry. ALSMA outperforms 88.33% of its industry peers.

ALSMA's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for ALSMA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	76.7%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-3.54%

GM growth 5Y-12.33%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALSMA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ALSMA has about the same amount of shares outstanding.

Compared to 5 years ago, ALSMA has less shares outstanding

Compared to 1 year ago, ALSMA has an improved debt to assets ratio.

2.2 Solvency

ALSMA has an Altman-Z score of 4.36. This indicates that ALSMA is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of ALSMA (4.36) is better than 76.67% of its industry peers.

ALSMA has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.

ALSMA's Debt to Equity ratio of 0.26 is in line compared to the rest of the industry. ALSMA outperforms 55.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	N/A
Altman-Z	4.36

ROIC/WACCN/A

WACC7.87%

2.3 Liquidity

ALSMA has a Current Ratio of 2.71. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 2.71, ALSMA is doing good in the industry, outperforming 76.67% of the companies in the same industry.

A Quick Ratio of 2.27 indicates that ALSMA has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 2.27, ALSMA belongs to the top of the industry, outperforming 81.67% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.71
Quick Ratio	2.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALSMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -320.37%.

The Revenue has been growing slightly by 2.12% in the past year.

The Revenue has been growing by 69.73% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-320.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%30.66%

Revenue 1Y (TTM)2.12%

Revenue growth 3Y37.17%

Revenue growth 5Y69.73%

Sales Q2Q%137.15%

3.2 Future

Based on estimates for the next years, ALSMA will show a very strong growth in Earnings Per Share. The EPS will grow by 43.73% on average per year.

The Revenue is expected to grow by 36.55% on average over the next years. This is a very strong growth

EPS Next Y48.75%

EPS Next 2Y55.72%

EPS Next 3Y39.46%

EPS Next 5Y43.73%

Revenue Next Year81.82%

Revenue Next 2Y61.25%

Revenue Next 3Y50.1%

Revenue Next 5Y36.55%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALSMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALSMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALSMA's earnings are expected to grow with 39.46% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y55.72%

EPS Next 3Y39.46%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALSMA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SMAIO SA

EPA:ALSMA (11/11/2025, 7:00:00 PM)

6.45

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap36.44M

Revenue(TTM)5.50M

Net Income(TTM)-2.35M

Analysts86

Price Target8.26 (28.06%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)11.72%

PT rev (3m)11.72%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-32.26%

EPS NY rev (3m)-86.36%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-6.54%

Revenue NY rev (3m)-6.54%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	6.63
P/FCF	N/A
P/OCF	N/A
P/B	5.32
P/tB	7.95
EV/EBITDA	N/A

EPS(TTM)-0.45

EYN/A

EPS(NY)-0.21

Fwd EYN/A

FCF(TTM)-0.53

FCFYN/A

OCF(TTM)-0.25

OCFYN/A

SpS0.97

BVpS1.21

TBVpS0.81

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-19.91%
ROE	-34.3%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	76.7%
FCFM	N/A

ROA(3y)0.22%

ROA(5y)-14.26%

ROE(3y)-3.31%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-3.54%

GM growth 5Y-12.33%

F-Score4

Asset Turnover0.47

Health

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	119.44%
Cap/Sales	28.27%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.71
Quick Ratio	2.27
Altman-Z	4.36

F-Score4

WACC7.87%

ROIC/WACCN/A

Cap/Depr(3y)98.78%

Cap/Depr(5y)137.67%

Cap/Sales(3y)30.2%

Cap/Sales(5y)56.86%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-320.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%30.66%

EPS Next Y48.75%

EPS Next 2Y55.72%

EPS Next 3Y39.46%

EPS Next 5Y43.73%

Revenue 1Y (TTM)2.12%

Revenue growth 3Y37.17%

Revenue growth 5Y69.73%

Sales Q2Q%137.15%

Revenue Next Year81.82%

Revenue Next 2Y61.25%

Revenue Next 3Y50.1%

Revenue Next 5Y36.55%

EBIT growth 1Y-200.73%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year90%

EBIT Next 3Y55.78%

EBIT Next 5Y44.66%

FCF growth 1Y-153.16%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-517.2%

OCF growth 3YN/A

OCF growth 5YN/A

SMAIO SA / ALSMA.PA FAQ

What is the fundamental rating for ALSMA stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALSMA.PA.

What is the valuation status of SMAIO SA (ALSMA.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to SMAIO SA (ALSMA.PA). This can be considered as Overvalued.

How profitable is SMAIO SA (ALSMA.PA) stock?

SMAIO SA (ALSMA.PA) has a profitability rating of 1 / 10.

What is the earnings growth outlook for SMAIO SA?

The Earnings per Share (EPS) of SMAIO SA (ALSMA.PA) is expected to grow by 48.75% in the next year.

SMAIO SA (ALSMA.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

SMAIO SA / ALSMA.PA FAQ

What is the fundamental rating for ALSMA stock?

What is the valuation status of SMAIO SA (ALSMA.PA) stock?

How profitable is SMAIO SA (ALSMA.PA) stock?

What is the earnings growth outlook for SMAIO SA?